Overall Conclusion: Q3 results exceeded expectations, with the core drivers being an 18% increase in DaVinci procedure volume and a 15% increase in system placements.

Key Data: Revenue reached $2.0 billion (+17% YoY), EPS was $1.84 (+26% YoY), and procedure volume grew 18% (17% on an adjusted daily basis).

Business Progress: DaVinci 5 supply is gradually increasing, with 110 units placed in the U.S. and a full market launch expected by mid-2025. Ion procedure volume grew 73%, SP grew 70%, and international penetration accelerated. New facilities in Georgia and an India center were established, improving operational efficiency.

Guidance & Outlook: 2024 procedure volume growth guidance raised to 16%-17% (from the low end of 15.5%), operating expense growth rate lowered to 10%-12% (from the high end of 13%), and gross margin target of 68.5%-69%.

Risks/Highlights: Management is positive about early DaVinci 5 feedback, emphasizing efficiency improvements. However, local competition in China, strikes in South Korea, and European budget pressures continue to dampen growth, with a tone of cautious optimism.